Top News

Showa Shell Surges 29% After Idemitsu Acquisition Report
Tweet TWEET

Perrigo Confirms Settlement Of Generic Version Of Ofirmev® (acetaminophen) Injection Patent Litigation

  Perrigo Confirms Settlement Of Generic Version Of Ofirmev® (acetaminophen)
                         Injection Patent Litigation

PR Newswire

ALLEGAN, Mich., Nov. 28, 2012

ALLEGAN, Mich., Nov. 28, 2012 /PRNewswire/ --Perrigo Company (Nasdaq: PRGO;
TASE) today announced that it has agreed to settle its Hatch-Waxman litigation
relating to Ofirmev® (acetaminophen) injection brought by Cadence
Pharmaceuticals, Inc. ("Cadence"). Under the terms of the settlement, Perrigo
can launch a generic version of Ofirmev® (acetaminophen) injection on December
6, 2020, or earlier under certain circumstances. In addition, Perrigo has
secured the right to be the sole authorized generic distributor should Cadence
elect to launch an authorized generic product.

(Logo: http://photos.prnewswire.com/prnh/20120301/DE62255LOGO )

Ofirmev® (acetaminophen) injection is administered intravenously as a single
or repeated dose therapy for the reduction of fever and the treatment of mild
to severe pain with or without adjunctive opioid analgesics. Ofirmev® has
annual sales of approximately $42 million, as measured by Wolters Kluwer.

Perrigo's Chairman, President and CEO Joseph C. Papa stated, "This settlement
is another example of our long-term investment in extended product
development. Perrigo continues its commitment to making quality healthcare
more affordable for our customers."

From its beginnings as a packager of generic home remedies in 1887, Perrigo
Company, based in Allegan, Michigan, has grown to become a leading global
provider of quality, affordable healthcare products. The Company develops,
manufactures and distributes over-the-counter ("OTC") and generic prescription
("Rx") pharmaceuticals, nutritional products and active pharmaceutical
ingredients ("API") and is the world's largest manufacturer of OTC
pharmaceutical products for the store brand market. Perrigo's mission is to
offer uncompromised "quality, affordable healthcare products", and it does so
across a wide variety of product categories primarily in the United States,
United Kingdom, Mexico, Israel and Australia, as well as certain other markets
throughout the world, including Canada, China and Latin America. Visit Perrigo
on the Internet (http://www.perrigo.com).

Note: Certain statements in this press release are forward-looking statements
within the meaning of Section 21E of the Securities Exchange Act of 1934, as
amended, and are subject to the safe harbor created thereby. These statements
relate to future events or the Company's future financial performance and
involve known and unknown risks, uncertainties and other factors that may
cause the actual results, levels of activity, performance or achievements of
the Company or its industry to be materially different from those expressed or
implied by any forward-looking statements. In some cases, forward-looking
statements can be identified by terminology such as "may," "will," "could,"
"would," "should," "expect," "plan," "anticipate," "intend," "believe,"
"estimate," "predict," "potential" or other comparable terminology. The
Company has based these forward-looking statements on its current
expectations, assumptions, estimates and projections. While the Company
believes these expectations, assumptions, estimates and projections are
reasonable, such forward-looking statements are only predictions and involve
known and unknown risks and uncertainties, many of which are beyond the
Company's control. These and other important factors, including those
discussed under "Risk Factors" in the Company's Form 10-K for the year ended
June 30, 2012, as well as the Company's subsequent filings with the Securities
and Exchange Commission, may cause actual results, performance or achievements
to differ materially from those expressed or implied by these forward-looking
statements. The forward-looking statements in this press release are made only
as of the date hereof, and unless otherwise required by applicable securities
laws, the Company disclaims any intention or obligation to update or revise
any forward-looking statements, whether as a result of new information, future
events or otherwise.

SOURCE Perrigo Company

Website: http://www.perrigo.com
Contact: Arthur J. Shannon, Vice President, Investor Relations and
Communication, +1-269-686-1709, ajshannon@perrigo.com, or Bradley Joseph,
Senior Manager, Investor Relations and Communication, +1-269-686-3373,
bradley.joseph@perrigo.com
 
Press spacebar to pause and continue. Press esc to stop.